View in EDS

High levels of chromosomal aberrations negatively associate with benefit to checkpoint inhibition in NSCLC.

Saved in:
Bibliographic Details
Title: High levels of chromosomal aberrations negatively associate with benefit to checkpoint inhibition in NSCLC.
Authors: Frigola J; Thoracic Cancers Translational Genomics Unit, Vall d'Hebron Institute of Oncology (VHIO), Barcelona, Spain.; Clinical Research Department, Vall d'Hebron Institute of Oncology (VHIO), Barcelona, Spain., Carbonell C; Thoracic Cancers Translational Genomics Unit, Vall d'Hebron Institute of Oncology (VHIO), Barcelona, Spain.; Clinical Research Department, Vall d'Hebron Institute of Oncology (VHIO), Barcelona, Spain., Irazno P; Clinical Research Department, Vall d'Hebron Institute of Oncology (VHIO), Barcelona, Spain.; Oncology Department, Vall d'Hebron University Hospital, Barcelona, Spain., Pardo N; Clinical Research Department, Vall d'Hebron Institute of Oncology (VHIO), Barcelona, Spain.; Oncology Department, Vall d'Hebron University Hospital, Barcelona, Spain., Callejo A; Clinical Research Department, Vall d'Hebron Institute of Oncology (VHIO), Barcelona, Spain.; Oncology Department, Vall d'Hebron University Hospital, Barcelona, Spain., Cedres S; Clinical Research Department, Vall d'Hebron Institute of Oncology (VHIO), Barcelona, Spain.; Oncology Department, Vall d'Hebron University Hospital, Barcelona, Spain., Martinez-Marti A; Clinical Research Department, Vall d'Hebron Institute of Oncology (VHIO), Barcelona, Spain.; Oncology Department, Vall d'Hebron University Hospital, Barcelona, Spain., Navarro A; Clinical Research Department, Vall d'Hebron Institute of Oncology (VHIO), Barcelona, Spain.; Oncology Department, Vall d'Hebron University Hospital, Barcelona, Spain., Soleda M; Thoracic Cancers Translational Genomics Unit, Vall d'Hebron Institute of Oncology (VHIO), Barcelona, Spain.; Clinical Research Department, Vall d'Hebron Institute of Oncology (VHIO), Barcelona, Spain., Jimenez J; Molecular Oncology Group, Vall d'Hebron Institute of Oncology (VHIO), Barcelona, Spain., Hernandez-Losa J; Department of Pathology, Vall d'Hebron University Hospital, Barcelona, Spain., Vivancos A; Cancer Genomics Laboratory, Vall d'Hebron Institute of Oncology (VHIO), Barcelona, Spain., Felip E; Thoracic Cancers Translational Genomics Unit, Vall d'Hebron Institute of Oncology (VHIO), Barcelona, Spain ramat@vhio.net efelip@vhio.net.; Clinical Research Department, Vall d'Hebron Institute of Oncology (VHIO), Barcelona, Spain.; Oncology Department, Vall d'Hebron University Hospital, Barcelona, Spain., Amat R; Thoracic Cancers Translational Genomics Unit, Vall d'Hebron Institute of Oncology (VHIO), Barcelona, Spain ramat@vhio.net efelip@vhio.net.; Clinical Research Department, Vall d'Hebron Institute of Oncology (VHIO), Barcelona, Spain.
Source: Journal for immunotherapy of cancer [J Immunother Cancer] 2022 Apr; Vol. 10 (4).
Publication Type: Journal Article; Research Support, Non-U.S. Gov't
Journal Info: Publisher: BMJ Publishing Group Ltd Country of Publication: England NLM ID: 101620585 Publication Model: Print Cited Medium: Internet ISSN: 2051-1426 (Electronic) Linking ISSN: 20511426 NLM ISO Abbreviation: J Immunother Cancer Subsets: MEDLINE
Database: MEDLINE Ultimate
Description
ISSN:2051-1426
DOI:10.1136/jitc-2021-004197